206 related articles for article (PubMed ID: 23732621)
1. Octreotide prescribing patterns in the palliation of symptomatic inoperable malignant bowel obstruction patients at a single US academic hospital.
Hwang M; Pirrello R; Pu M; Messer K; Roeland E
Support Care Cancer; 2013 Oct; 21(10):2817-24. PubMed ID: 23732621
[TBL] [Abstract][Full Text] [Related]
2. Octreotide for malignant bowel obstruction: twenty years after.
Mercadante S; Porzio G
Crit Rev Oncol Hematol; 2012 Sep; 83(3):388-92. PubMed ID: 22277783
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction.
Shima Y; Ohtsu A; Shirao K; Sasaki Y
Jpn J Clin Oncol; 2008 May; 38(5):354-9. PubMed ID: 18490369
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer.
Kubota H; Taguchi K; Kobayashi D; Naruyama H; Hirose M; Fukuta K; Kubota Y; Yasui T; Yamada Y; Kohri K
Asian Pac J Cancer Prev; 2013; 14(12):7107-10. PubMed ID: 24460259
[TBL] [Abstract][Full Text] [Related]
5. A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer.
Watari H; Hosaka M; Wakui Y; Nomura E; Hareyama H; Tanuma F; Hattori R; Azuma M; Kato H; Takeda N; Ariga S; Sakuragi N
Int J Gynecol Cancer; 2012 May; 22(4):692-6. PubMed ID: 22343971
[TBL] [Abstract][Full Text] [Related]
6. Practice Patterns of Medications for Patients With Malignant Bowel Obstruction Using a Nationwide Claims Database and the Association Between Treatment Outcomes and Concomitant Use of H
Minoura T; Takeuchi M; Morita T; Kawakami K
J Pain Symptom Manage; 2018 Feb; 55(2):413-419.e2. PubMed ID: 29122616
[TBL] [Abstract][Full Text] [Related]
7. Clinician-reported changes in octreotide prescribing for malignant bowel obstruction as a result of an adequately powered phase III study: A transnational, online survey.
Campbell R; McCaffrey N; Brown L; Agar MR; Clark K; Currow DC
Palliat Med; 2018 Sep; 32(8):1363-1368. PubMed ID: 29856291
[TBL] [Abstract][Full Text] [Related]
8. Medical Therapy of Malignant Bowel Obstruction With Octreotide, Dexamethasone, and Metoclopramide.
Berger J; Lester P; Rodrigues L
Am J Hosp Palliat Care; 2016 May; 33(4):407-10. PubMed ID: 25646530
[TBL] [Abstract][Full Text] [Related]
9. Palliative Medical Management of Inoperable Malignant Bowel Obstruction With "Triple Therapy": Dexamethasone, Octreotide, and Metoclopramide.
Wey W; Mian M; Calabrese R; Hansen E; Walter M; Wang C; Miller A; Case AA
Am J Hosp Palliat Care; 2021 Apr; 38(4):340-345. PubMed ID: 33084354
[TBL] [Abstract][Full Text] [Related]
10. Palliative Management of Inoperable Malignant Bowel Obstruction: Prospective, Open Label, Phase 2 Study at an NCI Comprehensive Cancer Center.
Walter M; Hansen E; Hamid S; Carozza D; Mann G; Roche C; George A; Attwood K; Case A
J Pain Symptom Manage; 2024 Jan; 67(1):20-26. PubMed ID: 37769820
[TBL] [Abstract][Full Text] [Related]
11. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer.
Blair SL; Chu DZ; Schwarz RE
Ann Surg Oncol; 2001 Sep; 8(8):632-7. PubMed ID: 11569777
[TBL] [Abstract][Full Text] [Related]
12. Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis.
Mangili G; Aletti G; Frigerio L; Franchi M; Panacci N; Viganò R; DE Marzi P; Zanetto F; Ferrari A
Int J Gynecol Cancer; 2005; 15(5):830-5. PubMed ID: 16174232
[TBL] [Abstract][Full Text] [Related]
13. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.
Currow DC; Quinn S; Agar M; Fazekas B; Hardy J; McCaffrey N; Eckermann S; Abernethy AP; Clark K
J Pain Symptom Manage; 2015 May; 49(5):814-21. PubMed ID: 25462210
[TBL] [Abstract][Full Text] [Related]
14. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction.
Massacesi C; Galeazzi G
Palliat Med; 2006 Oct; 20(7):715-6. PubMed ID: 17060271
[TBL] [Abstract][Full Text] [Related]
15. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
Mystakidou K; Tsilika E; Kalaidopoulou O; Chondros K; Georgaki S; Papadimitriou L
Anticancer Res; 2002; 22(2B):1187-92. PubMed ID: 12168923
[TBL] [Abstract][Full Text] [Related]
16. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
Matulonis UA; Seiden MV; Roche M; Krasner C; Fuller AF; Atkinson T; Kornblith A; Penson R
J Pain Symptom Manage; 2005 Dec; 30(6):563-9. PubMed ID: 16376743
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide.
McCaffrey N; Asser T; Fazekas B; Muircroft W; Agar M; Clark K; Eckermann S; Lee J; Joshi R; Allcroft P; Sheehan C; Currow DC
BMC Cancer; 2020 Oct; 20(1):1050. PubMed ID: 33129304
[TBL] [Abstract][Full Text] [Related]
18. Medical Management of Inoperable Malignant Bowel Obstruction.
Huang X; Xue J; Gao M; Qin Q; Ma T; Li X; Wang H
Ann Pharmacother; 2021 Sep; 55(9):1134-1145. PubMed ID: 33345552
[TBL] [Abstract][Full Text] [Related]
19. Drainage Percutaneous Endoscopic Gastrostomy for Malignant Bowel Obstruction in Gastrointestinal Cancers: Prognosis and Implications for Timing of Palliative Intervention.
Pinard KA; Goring TN; Egan BC; Koo DJ
J Palliat Med; 2017 Jul; 20(7):774-778. PubMed ID: 28437204
[TBL] [Abstract][Full Text] [Related]
20. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.
Mercadante S; Ripamonti C; Casuccio A; Zecca E; Groff L
Support Care Cancer; 2000 May; 8(3):188-91. PubMed ID: 10789958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
